logo

For the Inventor, By the Inventor

Rye Brook, NY, United States of America

Lauric Haber

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 96(Granted Patents)


Company Filing History:

goldMedal14 out of 1,345 
 
Regeneron Pharmaceuticals, Inc.
 patents
silverMedal2 out of 49 
 
Regeneran Pharmaceuticals, Inc.
 patents

Years Active: 2019-2025

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 12441800 - Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof (2025-10-14),
2. 12415856 - EGFR x CD28 multispecific antibodies (2025-09-16),
3. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2025-07-01),
4. 12077603 - Multispecific antigen-binding molecules for cell targeting and uses thereof (2024-09-03),
5. 12065508 - Multispecific antigen-binding molecules for cell targeting and uses thereof (2024-08-20),
6. 11952430 - Multispecific antigen-binding molecules for cell targeting and uses thereof (2024-04-09),
7. 11912767 - EGFR × CD28 multispecific antibodies (2024-02-27),
8. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof (2023-04-25),
9. 11548947 - Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof (2023-01-10),
10. 11485793 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof (2022-11-01),
11. 11453721 - Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof (2022-09-27),
12. 11155633 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2021-10-26),
13. 10941208 - Anti-MUC16 antibodies (2021-03-09),
14. 10772972 - Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof (2020-09-15),
15. 10738130 - Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof (2020-08-11),

Title: Lauric Haber: Innovator in Bispecific Antibodies

Introduction

Lauric Haber is a prominent inventor based in Rye Brook, NY (US), known for his significant contributions to the field of immunotherapy. With a total of 16 patents to his name, he has made remarkable advancements in the development of bispecific antibodies aimed at treating various cancers.

Latest Patents

Haber's latest patents include innovative inventions such as bispecific anti-PSMA x anti-CD28 antibodies. This invention provides bispecific antigen-binding molecules that specifically target human CD28 and PSMA, which are crucial in inhibiting the growth of tumors expressing PSMA, particularly prostate tumors. These antibodies are designed to enhance targeted immune responses, making them therapeutically beneficial for treating diseases where such responses are desired. Another notable patent is the EGFR x CD28 multispecific antibodies, which bind to both EGFR and CD28. This invention allows for combination therapies with anti-PD1 antibodies, promoting effective treatment strategies for EGFR-expressing cancers. The combination therapy has shown to enhance T cell activation and improve anti-tumor efficacy without causing systemic cytokine secretion.

Career Highlights

Throughout his career, Lauric Haber has worked with leading companies in the pharmaceutical industry, including Regeneron Pharmaceuticals, Inc. His work has significantly impacted the development of immunotherapeutic modalities, particularly in the context of cancer treatment.

Collaborations

Haber has collaborated with notable professionals in his field, including Eric L. Smith and Alison Crawford. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Lauric Haber stands out as an influential inventor in the realm of bispecific antibodies, with a focus on innovative cancer therapies. His contributions continue to shape the future of immunotherapy, providing hope for improved treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…